Theravance Biopharma, Inc. (NASDAQ:TBPH) Weekly Ratings on May 17, 2018

May 17, 2018 - By Elliot Rainer

Theravance Biopharma, Inc. (NASDAQ:TBPH) Corporate Logo
During 2017 Q4 the big money sentiment decreased to 1.31. That’s change of 0.01, from 2017Q3’s 1.32. 7 investors sold all, 22 reduced holdings as Theravance Biopharma, Inc. ratio is negative. 26 grew stakes while 12 funds took stakes. Funds hold 35.06 million shares thus 1.11% less from 2017Q3’s 35.46 million shares.
Balyasny Asset Mgmt Ltd Com owns 88,692 shs. Credit Suisse Ag has invested 0% of its capital in Theravance Biopharma, Inc. (NASDAQ:TBPH). Massachusetts-based State Street Corp has invested 0% in Theravance Biopharma, Inc. (NASDAQ:TBPH). Legal General Group Public Ltd Limited Liability Company reported 21,140 shs. Tower Limited (Trc) holds 0% or 546 shs. Parametric Port Assocs Limited Liability Company holds 0% in Theravance Biopharma, Inc. (NASDAQ:TBPH) or 19,434 shs. Geode Management Ltd stated it has 0% in Theravance Biopharma, Inc. (NASDAQ:TBPH). Qs Invsts Ltd Llc holds 0% or 2,500 shs in its capital. Barclays Pcl has invested 0% in Theravance Biopharma, Inc. (NASDAQ:TBPH). California Pub Employees Retirement reported 0% stake. Moreover, Rock Springs Cap Lp has 0.83% invested in Theravance Biopharma, Inc. (NASDAQ:TBPH). Illinois-based Envestnet Asset Mgmt has invested 0% in Theravance Biopharma, Inc. (NASDAQ:TBPH). Morgan Stanley has 0% invested in Theravance Biopharma, Inc. (NASDAQ:TBPH) for 96,237 shs. Savings Bank Of America De has 0% invested in Theravance Biopharma, Inc. (NASDAQ:TBPH) for 33,683 shs. Senzar Asset Llc holds 1.22% of its capital in Theravance Biopharma, Inc. (NASDAQ:TBPH) for 171,800 shs.

Theravance Biopharma, Inc. (NASDAQ:TBPH) Ratings Coverage

Total analysts of 3 have positions in Theravance Biopharma (NASDAQ:TBPH) as follows: 3 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since February 8, 2018 according to StockzIntelligence Inc Theravance Biopharma has 4 analyst reports. In Tuesday, May 8 report Cantor Fitzgerald maintained it with “Buy” rating and $5500 target. On Tuesday, February 27 the stock of Theravance Biopharma, Inc. (NASDAQ:TBPH) earned “Buy” rating by Cantor Fitzgerald. The company rating was initiated by Piper Jaffray on Thursday, March 29. On Thursday, February 8 the firm has “Outperform” rating by Leerink Swann given. Listed here are Theravance Biopharma, Inc. (NASDAQ:TBPH) PTs and latest ratings.

08/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $55.0000 Maintain
29/03/2018 Broker: Piper Jaffray Rating: Buy New Target: $45.0000 Initiate
27/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $55.0 Maintain
08/02/2018 Broker: Leerink Swann Rating: Outperform Old Target: $45 New Target: $48 Maintain

Ticker’s shares touched $24.35 during the last trading session after 1.30% change.Theravance Biopharma, Inc. has volume of 175,081 shares. Since May 17, 2017 TBPH has declined 26.76% and is downtrending. The stock underperformed the S&P 500 by 38.31%.

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics.The company has $1.34 billion market cap. The firm offers VIBATIV , a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria.Last it reported negative earnings. The Company’s product candidates include TD-1792 that is in phase III clinical trials for the treatment of skin and soft tissues infections; TD-6450, a multivalent NS5A inhibitor, which is in Phase II study for Hepatitis C Virus; and Revefenacin (TD-4208), a long acting muscarinic antagonist that is in Phase III clinical studies for chronic obstructive pulmonary diseases.

More recent Theravance Biopharma, Inc. (NASDAQ:TBPH) news were posted by Prnewswire.com, Seekingalpha.com and Streetinsider.com. The first one has “Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical …” as a title and was posted on April 20, 2018. The next is “Theravance Biopharma’s (TBPH) CEO Rick Winningham on Q1 2018 Results – Earnings Call Transcript” on May 09, 2018. And last was posted on April 25, 2018, called “Theravance Biopharma (TBPH) Announces Approval of Expanded Indication in US for Once-Daily Trelegy Ellipta for …”.

Theravance Biopharma, Inc. (NASDAQ:TBPH) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.